Company Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company’s platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.
The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 174 |
| CEO | Stephen Dilly |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
| Phone | 650 421 8100 |
| Website | codexis.com |
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| Employer ID | 71-0872999 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stephen George Dilly MBBS, Ph.D. | President, Chief Executive Officer and Chairman |
| Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
| Dr. Alison Moore Ph.D. | Chief Technology Officer |
| Georgia L. Erbez | Chief Financial Officer |
| Carrie McKim | Director of Investor Relations |
| Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
| Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
| John Schiffhauer | Senior Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 22, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | 10-Q | Quarterly Report |